Home

FAQ

1.Where is Tengion headquartered?
2.What year was Tengion incorporated and in what state?
3.On what exchange is Tengion listed and under what stock symbol?
4.How can I purchase shares?
5.When does the fiscal year end?
6.Who is Tengion’s transfer agent?
7.Who are Tengion’s independent auditors?
8.Who is Tengion’s outside legal counsel?
9.Who should I contact if I have any questions?
1.Where is Tengion headquartered?
 Tengion is headquartered in Winston-Salem, North Carolina.

2.What year was Tengion incorporated and in what state?
 Tengion was incorporated in the State of Delaware on July 10, 2003.

3.On what exchange is Tengion listed and under what stock symbol?
 Tengion is traded on the OTC Markets under the symbol TNGN.

4.How can I purchase shares?
 Shares can be purchased through a stockbroker of your choice. Tengion does not have a direct stock purchase plan.

5.When does the fiscal year end?
 December 31

6.Who is Tengion’s transfer agent?
 Tengion's Transfer Agent and Registrar is American Stock Transfer and Trust Company (www.amstock.com; 800-937-5449)

7.Who are Tengion’s independent auditors?
  Ernst and Young
Two Commerce Square
2001 Market Street, Suite 4000
Philadelphia, PA 19103
(215) 448-5000

8.Who is Tengion’s outside legal counsel?
 Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
(617) 951-7000

9.Who should I contact if I have any questions?
 Brian Davis
Chief Financial Officer and Senior Vice President, Finance
ir@tengion.com

Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.19
Change (%) Stock is Up 0.01 (5.56%)
Volume41,400
Data as of 04/17/14 2:59 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
March 26, 2014
Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
WINSTON-SALEM, N.C., March 26, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2013 and provided a business update. "We made important progress on our two lead clinical programs over the last year. We now have two Phase 1 clinical trials ongoing for the Neo-Kidney Augment, one in Sweden and the other recently initiated in the U.S. to implant up to 12 patients. ... 
March 04, 2014
Tengion to Present at the 26th Annual ROTH Conference
WINSTON-SALEM, N.C., March 4, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 26th Annual ROTH Conference on Monday, March 10, 2014, at 12:30 p.m. PDT in Dana Point, CA. A live audio webcast of the presentation can be accessed at http://wsw.com/webcast/roth28/TNGN or under "Calendar of Events" in the Investors & News section of the Co...